BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.
BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.